All
Sylentis announces topline results of SYL1801 phase 2a study
SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.
Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with GA
A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.
LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System
Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.
Kapil Mishra discusses radiation retinopathy in uveal melanoma
Kapil Mishra, MD, discusses an overview of radiation retinopathy and its challenges in treating uveal melanoma from his presentation "Radiation Retinopathy: Future Strategies,"
Living with GA: How patients in the US and Western Europe cope
A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.
Role of AI, global collaboration in ophthalmology's future
Duke professor Sharon Fekrat, MD, discusses AI-driven ophthalmology with smartphone diagnostics and robotic procedures, emphasizing global collaboration and innovative medical research.
Hypoglycemia may promote a breakdown of the blood-retinal barrier
New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.
Positive preclinical data on melanocortin agonists for retinopathy
Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.
New research raises questions about the current clinical approach to inherited retinal diseases
Alfredo Sadun, MD, PhD, details a fascinating outcome from a gene therapy in development for Leber hereditary optic neuropathy.
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
The company shared results from the AAVB-081 clinical program and AAVB-039 preclinical program at ARVO.
The role of OCTA in detecting retinal microvascular abnormalities in SLE patients
The biomarkers are especially crucial for patients with lupus nephritis.
Status of baseline central subfield ellipsoid zone predictive of future visual loss
Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.
Patient comfort and using chlorhexidine for anti-sepsis
Boehringer Ingelheim launches two Phase 2 clinical trials for its geographic atrophy treatment candidates
Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.
Q&A: Katherine Talcott, MD, on exploring a potential connection between autoimmune diseases and AMD
RWC 2025: Update on the VERONA trial for diabetic macula edema
Q&A: Alan J. Franklin, MD, PHD, speaks to the use of intraoperative fluorescein angiography
RWC 2025: Updates on the HELIOS trial for diabetic retinopathy
At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs).
Optigo Bio receives People’s Choice Award for its proprietary drug anchoring
Optigo Biotherapeutics presents promising preclinical data at ARVO.
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.
Phase 2 DAWN for XLRP data presented at ARVO 2025
Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.
Assessment of AI-enabled screening for ROP in low-resource settings
Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.
Alkeus Pharmaceuticals presents additional data from Phase 2 clinical SAGA study for GA
Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.
Positive interim pilot clinical trial results of PYK-2101
Pykus Therapeutics reveals promising results for PYK-2101, a retinal sealant that enhances recovery and improves patient experience in retinal detachment surgery.
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME
The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.
ARVO 2025: Carl Danzig, MD, recaps the first stage of a phase 3 study of drop-based DME therapy
According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.
Topcon announces launch of IDHea
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.
Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101
The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.
Phase 2 BETTER trial results shared at ARVO 2025
Innovent Biologics announced latest data on IBI302
The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.
